Mark R. Gilbert

Research interests

Publications

• RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults

  Journal of Clinical Oncology · 2023 · https://doi.org/10.1200/jco.23.01059

• Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

  Neuro-Oncology · 2020 · https://doi.org/10.1093/neuonc/noaa106

• cIMPACT‐NOW update 7: advancing the molecular classification of ependymal tumors

  Brain Pathology · 2020 · https://doi.org/10.1111/bpa.12866

• Longitudinal molecular trajectories of diffuse glioma in adults

  Nature · 2019 · https://doi.org/10.1038/s41586-019-1775-1

• Challenges to curing primary brain tumours

  Nature Reviews Clinical Oncology · 2019 · 10.1038/s41571-019-0177-5

• MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

  Clinical Cancer Research · 2018 · https://doi.org/10.1158/1078-0432.ccr-18-3181

• Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG

  Neuro-Oncology · 2017 · https://doi.org/10.1093/neuonc/nox025

• Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2015.63.6563

• Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups

  Cancer Cell · 2015 · https://doi.org/10.1016/j.ccell.2015.04.002

• Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00088-1

• MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints

  Neuro-Oncology · 2015 · https://doi.org/10.1093/neuonc/nov292

• Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials

  Neuro-Oncology · 2015 · 10.1093/neuonc/nov095

• A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1308573

• Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2013.49.6968

• Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas

  Cancer Immunology Research · 2013 · https://doi.org/10.1158/2326-6066.cir-13-0028

• Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.26.3541

• Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2010.28.6963

• Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

  Neuro-Oncology · 2010 · https://doi.org/10.1093/neuonc/noq157

• Correlation of O 6 -Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2007.11.5964

• Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients

  Clinical Cancer Research · 2005 · https://doi.org/10.1158/1078-0432.ccr-04-1737

Current projects

No projects listed.